Cogent Biosciences Inc (NASDAQ:COGT)
| 9.98 Delayed Data As of Sep 25 |  -0.04 / -0.40%Today’s Change | 9.61 Today|||52-Week Range 15.68 | -13.67% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $855.9M |
Company Description
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
Contact Information
Cogent Biosciences, Inc. 275 Wyman Street Waltham Massachusetts 02451 |
Employees
Shareholders
| Other institutional | 58.02% |
| Individual stakeholders | 3.23% |
| Mutual fund holders | 25.77% |
Top Executives
| Andrew R. Robbins | President, Chief Executive Officer & Director |
| John L. Green | Chief Financial Officer |
| Jessica Sachs | Chief Medical Officer |
| John Edward Robinson | Chief Scientific Officer |
| Rachael Easton | Vice President & Head-Clinical Development |
